Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_4466_Библиотеки_им_академика_М_И_Перельмана

.pdf
Скачиваний:
0
Добавлен:
30.08.2026
Размер:
44 Мб
Скачать
464
https://t.me/medicina_free
T. A. Teke et al.
space. Corticosteroids have known potent activities in limiting inammation. Corticosteroids were used to manage bacterial meningitis to minimize the subarach­noid space inammation and decrease several manifestations such as vasogenic brain edema, increased intracranial pressure, cerebral blood ow changes, cerebral vasculitis, and neuronal injury [2325]. The effect of corticosteroids on mortality rate, HL, and other neurologic sequelae has been evaluated. Proof of clinical advan­tage was most prominent for audiologic results.
Numerous clinical trials focused on the impacts of corticosteroids on audiologic outcomes in patients with Hib meningitis. In a double-blind, placebo-controlled research, patients were given cefuroxime or ceftriaxone in addition to either dexa­methasone or placebo, 13 of 84 placebo group patients (15%), and 3 of 92 patients in the dexamethasone group (3.3%) had moderate or more severe bilateral HL.The efcacy of dexamethasone on SNHL was documented only for patients having Hib meningitis. In this study, there were too few patients with meningitis by other organ­isms to assess whether dexamethasone has the same effect in these cases [26]. One prospective, multicenter, placebo-controlled clinical trial with 143 children with bacterial meningitis demonstrated no signicant overall difference between patients given dexamethasone and those given a placebo for SNHL. The only subgroup where a benet was observed with dexamethasone was that of patients with Hib meningitis [27]. In the following years, several reviews of the studies advocated the benet of supplementary dexamethasone in hearing outcomes of infants and chil­dren suspected or proven to have Hib meningitis [2830].
In 2010, a meta-analysis of 24 studies involving 4041 participants showed that corticosteroids obviated severe HL and any HL in children with bacterial meningi­tis. Analysis of subgroups for causative organisms indicated that corticosteroids minimized severe HL in Hib meningitis [31]. A recent meta-analysis of 25 studies involving 4121 participants (2511 pediatric patients, most children had meningitis due to Hib) showed that corticosteroids minimized severe HL in children with Hib meningitis but not in children with meningitis of non-Haemophilus species. Further analysis of the country’s income level where the individual studies were conducted indicated that dexamethasone decreased the severe HL rate among children in high­income countries but not in low and middle-income countries [11].
In experimentally induced Hib meningitis, a single ceftriaxone dose given intra­venously resulted in a signicant increase in LOS and tumor necrosis factor-alpha (TNF-α) concentrations in CSF 2 h later, as compared with the levels in untreated animals. Dexamethasone signicantly reduced TNF-α concentrations and indexes of meningeal inammation in CSF when administered with antibiotic simultane­ously, but not if it was given 1h later [32]. Similarly, concentrations of free endo­toxin and TNF-α in CSF increased 2–6 h after the rst dose of ceftriaxone in infants with Hib meningitis [33]. In another placebo-controlled, double-blind trial of dexa­methasone treatment in Hib meningitis, including 101 infants and children, patients received either dexamethasone or a placebo with cefotaxime. When dexamethasone was administered before the initiation of cefotaxime treatment (15–20min before), the indexes of meningeal inammation and concentrations of cytokines in CSF improved rapidly and signicantly compared with the patients given only
30 Haemophilus inuenzae Type b Meningitis inChildren andHearing Loss
https://t.me/medicina_free
465
cefotaxime [34]. It is generally recommended that adjunctive dexamethasone be benecial if given just before or concurrently with the rst antimicrobial agent(s) dose in Hib meningitis [28]. It can be explained by the rapid killing of bacteria in the CSF, which releases toxic cell products and can lead to additional neurologic injury [35].
In the early stages of bacterial meningitis, SNHL typically develops and pro­gresses within 48h [3638]. Histopathologic studies in animals with Hib meningitis indicate that labyrinthitis is a probable cause of SNHL [36, 39]. The pathophysiol­ogy of labyrinthitis associated with bacterial meningitis was investigated by histo­pathologically examining the inner ears of 114 rats with Hib meningitis [36]. Except for the endolymphatic space, cochlear nerve bers, and middle ear, the perilym­phatic spaces of the cochlea and semicircular canals were inamed. The inamma­tion reached a peak 48h after inoculation. Immunouorescent staining of cochleae demonstrated the presence of bacteria in the inamed areas and the endolymphatic space and organ of Corti. In a histopathology study of 41 human temporal bones after death from acute bacterial meningitis, 20 (41%) temporal bones had suppura­tive labyrinthitis, and the cochlea was affected [40]. While the cochlear aqueduct was the sole pathway for spreading infection in the rabbit, in humans, the modiolus and the aqueduct were potential pathways suggested. It is mainly accepted that the transmission of infection from the subarachnoid space to the labyrinth is the cause of HL, and both the cochlear aqueduct and the cochlear nerve in the modiolus are the potential pathways of the infection extension [41]. Inammatory cell inltra­tion, serobrinous exudate formation, and granulation cells also indicate cochlear pathology [4143]. Vascular events such as septic emboli and thrombotic occlusion of the cochlear artery and vein result in cochlear hypoxia, ischemia, and neural damage [44]. Inammatory products such as nitric oxide and superoxide induce cytotoxic injury on the cochlea by destroying the blood–labyrinth barrier [9].
Diagnostic techniques of SNHL are complementary and vary according to the patient’s developmental age (cooperative or uncooperative). As soon as SNHL is identied through the screening, age-appropriate testing will be implemented. If a child cannot complete behavioral audiometric tests, otoacoustic emission (OAE) and brainstem auditory evoked response (BAER) testing should be performed, which requires more time and expertise to interpret but elicits more detailed infor­mation [45]. Otoacoustic emission tests are rapid and easy to perform. According to the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines, OAE is used for screening children with bacterial meningitis [12]. In case of failure, children are referred for a further hearing evaluation, such as BAER testing or speech tone audiometry, according to the patient’s age [12].
Imaging the temporal bone and cochlea are needed for profound SNHL after meningitis before cochlear implantation [46]. Computed tomography (CT) or mag­netic resonance (MR) imaging may be done depending on the decision of the oto­laryngologist. Magnetic resonance imaging can visualize the detailed inner ear anatomy and allows for rapid cochlear implantation if a risk of cochlear obliteration presents itself [47]. Gadolinium-enhanced MR imaging effectively predicted SNHL by detecting labyrinthitis in the early phase of bacterial meningitis in children [48].
466
https://t.me/medicina_free
Sensorineural HL rehabilitation is vital for normal speech and language and the child’s educational and social development. Cochlear implantation is a treatment option in patients with bilateral SNHL after bacterial meningitis [47]. A cochlear implant is a neuroprosthetic device surgically implanted to stimulate the auditory nerve. Cochlear implantation is approved by the USA Food and Drug Administration (FDA) for children aged 12–24months with profound bilateral SNHL and those older than 24months with bilateral severe to profound SNHL.No FDA approval exists for implantation in children below 12months of age. Implantation candidates are also determined through comprehensive audiologic and developmental evalua­tion [49]. Since any delay decreases the success rates of cochlear implantation because of cochlear brosis and calcication, early determination of SNHL second­ary to meningitis is crucial [44].
There is a consensus that SNHL should be detected early, and if detected, it should be monitored regularly. Various suggestions exist for the long-term audio­logic follow-up of patients with no SNHL at the initial assessment [5053]. Some countries do not recommend further testing in case of a normal initial hearing test after meningitis [50]. Conversely, several hearing evaluations are recommended after bacterial meningitis in other countries [51]. The ESCMID guideline recom­mends follow-up testing in patients with no SNHL during the initial hospitalization [12]. Spontaneous SNHL regressions, uctuations, or progressions may also be observed after recovery from meningitis [41, 42]. A study reported that 8% (5 of 64) and 10% (7 of 71) of children with Hib meningitis had profound SNHL in short- and long-term follow-ups [16]. Another study described progressive HL over 11years following Hib meningitis [52]. Close monitoring seems helpful for SNHL in patients with Hib meningitis.
T. A. Teke et al.
30.10 Postexposure Chemoprophylaxis
Postexposure prophylaxis is important for preventing secondary cases. High-risk groups for secondary infection are unimmunized or incompletely immunized chil­dren exposed to invasive Hib disease in childcare or household settings [8]. Children below the age of 4years are at higher risk for Hib disease following household contact [2]. Chemoprophylaxis can eliminate nasopharyngeal colonization and reduce invasive Hib disease risk in susceptible people [1].
Rifampin has been reported to eradicate Hib from the nasopharynx in nearly 95% of carriers. Studies have also demonstrated its effectiveness in preventing sec­ondary invasive Hib cases [6]. A dose of rifampin at 20mg/kg once daily orally (600mg maximum) for 4 days, administered for Hib prophylaxis, should be initi­ated as soon as possible [6]. Prophylaxis with rifampin is to be used for all house­hold contacts in the following conditions: in households having at least one infant below 12months with incomplete primary Hib vaccine series, in households with at least one child below 4 years that are not fully vaccinated, and in families with an immunocompromised child regardless of their Hib immunization status or age. In addition, prophylaxis is recommended for all contacts if two or more invasive Hib
30 Haemophilus inuenzae Type b Meningitis inChildren andHearing Loss
https://t.me/medicina_free
disease cases happen within 60days in attendees of a childcare facility and incom­pletely vaccinated children attend the facility. If the index patient is below 2 years old or a household member with susceptible contact and was treated with a regimen other than cefotaxime or ceftriaxone, prophylaxis will be given at the end of the treatment. As per the immunization schedule, unimmunized or incompletely immu­nized children are supposed to receive the Hib vaccine.
467
30.11 Prevention
Routine use of Hib vaccines in infants and children is the most effective prevention method for meningitis. The Hib conjugate vaccine is produced with the conjugation of the Hib capsular polysaccharide PRP to carrier proteins. Conjugate vaccines are highly effective for invasive Hib infections in infants and children. Besides their preventive effects, these vaccines prevent nasopharyngeal colonization with Hib and provide herd immunity [4]. The Hib conjugate vaccine doses are administered at 8 weeks intervals (a minimum of 4weeks) [8]. The primary series of Hib vaccines have either three doses, administered at 2, 4, and 6months of age, or two doses at 2 and 4months, depending on the vaccine products. The rst dose may also be admin­istered at 6 weeks of age. A booster dose is administered between 12 and 15months of age. High-risk groups for invasive Hib disease include children with sickle cell disease, functional or anatomic asplenia, human immunodeciency virus (HIV) infection, certain immunodeciency syndromes, bone marrow transplants, and patients receiving chemotherapy [6].
30.12 Conclusion
In children, bacterial meningitis is the leading cause of acquired SNHL [44]. The administration of conjugate vaccines has led to a dramatic decrease in the incidence of Hib meningitis. Despite effective antimicrobial treatment and timely administra­tion of dexamethasone, SNHL may occur in patients with Hib meningitis, so the increased effort for vaccination is essential in preventing the disease. Sensorineural HL has several long-term complications, including speech and language difculties and intellectual and behavioral disabilities. So, the early determination of HL is critical. Sensorineural HL caused by meningitis can be subtle, especially in infants. Routine follow-up after bacterial meningitis should include a hearing evaluation. There should be a prompt referral of children recovering from bacterial meningitis for audiologic assessment. When SNHL is detected, the child is evaluated for cochlear implantation, the current surgical management of children with SNHL.If there is no HL in initial hearing tests, it is unclear whether follow-up testing is needed. Because uctuations or progressions of SNHL are reported after bacterial meningitis, close follow-up is required.
468
https://t.me/medicina_free
T. A. Teke et al.
References
1. Kadry NA, Geme JW 3rd. Haemophilus inuenzae. In: Long SS, Prober CG, Fischer M, Kimberlin D, editors. Principles and practice of pediatric infectious diseases. 6th ed. Philadelphia: Elsevier; 2023. p.945–51.
2. Barenkamp SJ. Haemophilus inuenzae. In: Cherry J, Harrison GJ, Kaplan SL, Steinbach WJ, Hotez PJ, editors. Feigin and Cherry’s textbook of pediatric infectious diseases. 8th ed. Philadelphia: Elsevier; 2019. p.1199–211.
3. Oliver SE, Moro P, Blain AE.Haemophilus inuenzae. In: Hall E, Wodi AP, Hamborsky J, Morelli V, Schillie S, editors. Centers for Disease Control and Prevention Pink Book 2021: epidemiology and vaccine-preventable diseases. 14th ed. Washington, DC: Public Health Foundation; 2021. p. 111–24. https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/hib.
pdf. Accessed 25 Nov 2022.
4. Murphy TF. Haemophilus species, including H. inuenzae and H. ducreyi (chancroid). In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett’s principles and prac­tice of infectious diseases. 9th ed. Philadelphia: Elsevier; 2020. p.2743–52.
5. van de Beek D, Brouwer MC, Koedel U, Wall EC.Community-acquired bacterial meningitis. Lancet. 2021;398:1171–83.
6. American Academy of Pediatrics. Haemophilus inuenzae infections. In: Kimberlin DW, Barnett ED, Lyneld R, Sawyer MH, editors. Red Book: 2021–2024 report of the committee on infectious diseases. 32nd ed. Itasca, IL: American Academy of Pediatrics; 2021. p.345–54.
7. Abou-Hanna J, Panning K, Mehta H. Haemophilus inuenza type f meningitis complicated by bilateral subdural empyema, central venous thrombosis, and bilateral sensorineural hearing loss in an immunocompetent 12-month-old. Cureus. 2019;11:e4850.
8. Butler DF, Myers AL.Changing epidemiology of Haemophilus inuenzae in children. Infect Dis Clin N Am. 2018;32:119–28.
9. Tan YC, Gill AK, Kim KS. Treatment strategies for central nervous system infections: an update. Expert Opin Pharmacother. 2015;16:187–203.
10. American Academy of Pediatrics. Systemic and topical antimicrobial dosing and dose forms. In: Bradley JS, Nelson JD, Barnett ED, etal., editors. 2022 Nelson’s pediatric antimicrobial therapy. 28th ed. Itasca, IL: American Academy of Pediatrics; 2022. p.273–306.
11. Brouwer MC, McIntyre P, Prasad K, van de Beek D.Corticosteroids for acute bacterial men­ingitis. Cochrane Database Syst Rev. 2015;2015(9):CD004405.
12. van de Beek D, Cabellos C, Dzupova O, etal. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. 2016;22:37–62.
13. Fortnum H, Davis A.Hearing impairment in children after bacterial meningitis: incidence and resource implications. Br J Audiol. 1993;27:43–52.
14. Taylor HG, Schatschneider C, Watters G. Acute-phase neurologic complications of Haemophilus inuenzae type b meningitis: association with developmental problems at school age. J Child Neurol. 1998;13:113–9.
15. Pomeroy SL, Holmes SJ, Dodge PR, etal. Seizures and other neurological sequela of bacterial meningitis in children. N Engl J Med. 1990;323:1651–7.
16. Ahmed ASMNU, Khan NZ, Hussain M, etal. Follow-up of cases of Haemophilus inuenza type b meningitis to determine its long-term sequelae. J Pediatr. 2013;163:44–9.
17. Zainel A, Mitchell H, Sadarangani M.Bacterial meningitis in children: neurological complica­tions, associated risk factors, and prevention. Microorganisms. 2021;9:535.
18. Ramakrishnan M, Ulland AJ, Steinhardt LC, Moïsi JC, Were F, Levine OS. Sequelae due to bacterial meningitis among African children: a systematic literature review. BMC Med. 2009;7:47.
19. Jatto ME, Adeyemo AA, Ogunkeyede SA, Lagunju IA, Nwaorgu OG. Pediatric hearing thresholds post-bacterial meningitis. Front Surg. 2020;7:36.
30 Haemophilus inuenzae Type b Meningitis inChildren andHearing Loss
https://t.me/medicina_free
20. Orman G, Kukreja MK, Vallejo JG, Desai N, Huisman TAGM, KralikSF.Accuracy of MR imaging for detection of sensorineural hearing loss in infants with bacterial meningitis. Am J Neuroradiol. 2020;41:1081–6.
21. Feldman WE, Ginsburg CM, Mc Cracken GH, etal. Relations of concentrations of Haemophilus inuenzae type b in cerebrospinal uid to late sequela of patients with meningitis. J Pediatr. 1982;100:209–12.
22. Mertsola J, Kennedy WA, Waagner D, etal. Endotoxin concentrations in cerebrospinal uid correlate with clinical severity and neurologic outcome of Haemophilus inuenzae type b men­ingitis. Am J Dis Child. 1991;145:1099–103.
23. Tunkel AR, Wispelwey B, Scheld WM.Bacterial meningitis: recent advances in pathophysiol­ogy and treatment. Ann Intern Med. 1990;112:610–23.
24. Tunkel AR, Scheld WM. Pathogenesis and pathophysiology of bacterial meningitis. Clin Microbiol Rev. 1993;6:118–36.
25. Tunkel AR. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39:1267–84.
26. Lebel MH, Freij BJ, Syrogiannopoulos GA, etal. Dexamethasone therapy for bacterial menin­gitis: results of two double-blind, placebo-controlled trials. N Engl J Med. 1988;319:964–71.
27. Wald ER, Kaplan SL, Mason EO, etal. Dexamethasone therapy for children with bacterial meningitis. Meningitis Study Group. Pediatrics. 1995;95:21–8.
28. Tunkel AR, Scheld WM.Acute bacterial meningitis. Lancet. 1995;346:1675–80.
29. Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis. N Engl J Med. 1997;336:708–16.
30. Wubbel L, McCracken GH. Management of bacterial meningitis: 1998. Pediatr Rev. 1998;19:78–84.
31. Brouwer MC, McIntyre P, Prasad K, van de Beek D.Corticosteroids for acute bacterial men­ingitis. Cochrane Database Syst Rev. 2010;2010(9):CD004405.
32. Mustafa MM, Ramilo O, Mertsola J, etal. Modulation of inammation and cachectin activity in relation to treatment of experimental Hemophilus inuenzae type b meningitis. J Infect Dis. 1989;160:818–25.
33. Arditi M, Ables L, Yogev R.Cerebrospinal uid endotoxin levels in children with H. inu- enzae meningitis before and after administration of intravenous ceftriaxone. J Infect Dis. 1989;160:1005–11.
34. Odio CM, Faingezicht I, Paris M, etal. The benecial effects of early dexamethasone admin­istration in infants and children with bacterial meningitis. N Engl J Med. 1991;324:1525–31.
35. Esposito S, Semino M, Picciolli I, Principi N.Should corticosteroids be used in bacterial men­ingitis in children? Eur J Pediatr Neurol. 2013;17:24–8.
36. Wiedermann BL, Hawkins EP, Johnson GS, Lamberth LB, Mason EO, Kaplan SL.Pathogenesis of labyrinthitis associated with Haemophilus inuenzae type b meningitis in infants rats. J Infect Dis. 1986;153:27–32.
37. Kaplan SL, Catlin FI, Weaver T, Feigin RD.Onset of hearing loss in children with bacterial meningitis. Pediatrics. 1984;73:575–8.
38. Vienny H, Despland PA, Liitschg J, Deonna T, Dutoit-Marco ML, Gander C.Early diagnosis and evolution of deafness in childhood bacterial meningitis: a study using brainstem auditory evoked potentials. Pediatrics. 1984;73:579–86.
39. Moxon ER, Smith AL, Averill DR, Smith DH. Haemophilus inuenzae meningitis in infant rats after intranasal inoculation. J Infect Dis. 1974;129:154–62.
40. Merchant SN, Gopen Q.A human temporal bone study of acute bacterial meningogenic laby­rinthitis. Am J Otol. 1996;17:375–85.
41. Du Y, WuX LL.Mechanisms of bacterial meningitis-related deafness. Drug Discov Today. 2006;3:115–8.
42. Kenna MA.Acquired hearing loss in children. Otolaryngol Clin N Am. 2015;48:933–53.
43. Beijen J, Casselman J, Joosten F, etal. Magnetic resonance imaging in patients with meningitis­induced hearing loss. Eur Arch Otorhinolaryngol. 2009;266:1229–36.
469
470
https://t.me/medicina_free
44. Wellman MB, Sommer DD, McKenna J.Sensorineural hearing loss in postmeningitic chil­dren. Otol Neurotol. 2003;24:907–12.
45. Hart CK, Choo DI.What is the optimal workup for a child with bilateral sensorineural hearing loss? Laryngoscope. 2013;123:809–10.
46. Roukema BY, Van Loon MC, Smits C, etal. Cochlear implantation after bacterial meningitis in infants younger than 9 months. Int J Otolaryngol. 2011;2011:845–79.
47. van Loon MC, Hensen EF, de Foer B, Smit CF, Witte B, Merkus P.Magnetic resonance imag­ing in the evaluation of patients with sensorineural hearing loss caused by meningitis: implica­tions for cochlear implantation. Otol Neurotol. 2013;34:845–54.
48. Kopelovich JC, Germiller JA, Laury AM, Shah SS, Pollock AN.Early prediction of postmen­ingitic hearing loss in children using magnetic resonance imaging. Arch Otolaryngol Head Neck Surg. 2011;137:441–7.
49. Liu CC, Anne S, Horn DL.Advances in management of pediatric sensorineural hearing loss. Otolaryngol Clin N Am. 2019;52:847–61.
50. Public Health England. Guidelines for surveillance and audiological referral of infants and children following newborn hearing screen. London: Public Health England; 2012. Updated 19 Jul 2019. https://www.gov.uk/government/publications/surveillance- and- audiological-
referral- guidelines. Accessed 25 Nov 2022.
51. Merkus P, Free RH, Mylanus EA, et al. Dutch Cochlear Implant Group (CI-ON) consensus protocol on postmeningitis hearing evaluation and treatment. Otol Neurotol. 2010;31:1281–6.
52. Silkes ED, Chabot J.Progressive hearing loss following Haemophilus inuenzae meningitis. Int J Pediatr Otorhinolaryngol. 1985;9:249–56.
53. Rodenburg-Vlot MB, Ruytjens L, Oostenbrink R, Goedegebure A, van der Schroeff MP.Systematic review: incidence and course of hearing loss caused by bacterial meningitis: in search of an optimal timed audiological follow-up. Otol Neurotol. 2016;37:1–8.
T. A. Teke et al.
Gram-Negative Bacterial Meningitis
https://t.me/medicina_free
inChildren andHearing Loss
EdanurYeşil, MustafaHacımustafaoğlu, EminSamiArısoy, andArmandoG.Correa
31.1 Introduction
The leading gram-negative bacteria causing acute bacterial meningitis (ABM) are
Neisseria meningitidis (meningococcus), Haemophilus inuenzae type b (Hib), Salmonella spp., Acinetobacter spp., Pseudomonas spp., and enteric gram-negative
bacilli, including mainly Escherichia coli, and Klebsiella spp. This chapter primar­ily focuses on ABM caused by gram-negative bacteria, with neurological complica­tions, especially hearing loss (HL), and its evaluation. In addition, the general characteristics of ABM will also be briey discussed to highlight the distinctive features of ABM caused by different pathogens.
E. Yeşil (*) Division of Pediatric Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Mersin University, Mersin, Türkiye e-mail: edanuryesil@mersin.edu.tr
M. Hacımustafaoğlu Division of Pediatric Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Uludağ University, Bursa, Türkiye e-mail: mkemal@uludag.edu.tr
E. S. Arısoy Division of Pediatric Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Kocaeli University, Kocaeli, Türkiye e-mail: emin.sami.arisoy@gmail.com
A. G. Correa Division of Academic General Pediatrics, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
Section of International and Destination Medicine, Texas Children’s Hospital, Houston, TX, USA e-mail: acorrea@bcm.edu
31
© The Author(s), under exclusive license to Springer Nature Switzerland AG 2023 A. E. Arısoy et al. (eds.), Hearing Loss in Congenital, Neonatal and Childhood Infections, Comprehensive ENT, https://doi.org/10.1007/978-3-031-38495-0_31
471
472
https://t.me/medicina_free
E. Yeşil et al.
31.2 Etiology
Gram-negative bacteria, mainly N. meningitidis, Hib, and E. coli, are the signicant agents of ABM.Gram-negative bacilli are among the common causes of ABM, especially in newborns and infants younger than 3 months [1]. Gram-negative bacilli are a common cause of healthcare-associated meningitis but rare as community- acquired meningitis causes in older children and adults [2]. Gram­negative bacteria may cause infection in immunocompromised children and chil­dren with a ventriculoperitoneal shunt (VPS).
Pseudomonas species meningitis may occur following chronic cranial osteomy­elitis, a rare complication of mastoiditis or trauma, and may also be seen in children with immunodeciencies. Citrobacter diversus is a rare cause of meningitis in new­born infants but is associated with signicant morbidity and mortality. One-third of newborns with Citrobacter meningitis die, and most survivors have signicant neu- rological sequelae. Brain abscess is a common complication in neonatal C. diversus meningitis [3]. Citrobacter freundii and C. diversus are rare causes of meningitis in children and adults [2].
31.3 Epidemiology
In a surveillance study conducted in the United States of America (USA) between 2006 and 2007, the annual incidence of ABM was 81/100,000in children <2months, 7/100,000 between 2 months and 2 years, 0.6/100,000 in 2–10 years, and
0.4/100,000in 11–17years [4]. After the immunization programs for Hib and pneu­mococci with conjugate vaccines, the incidence of ABM decreased in all age groups. However, the incidence remains high in infants under 2months of age, where the effects of vaccines have not yet been seen [2].
Infants less than 3months (90days) are more vulnerable to infections than the other age groups. Causative pathogens of meningitis may vary according to age [58]:
• Newborn (0–28days): Group B streptococcus (GBS), E. coli, and other gram-
negative bacilli are the primary causative pathogens in neonatal ABM.
• Infants <3months (29–90days): Group B streptococcus, E. coli, other enteric
gram-negative bacilli, Streptococcus pneumoniae (pneumococcus), N. menin-
gitidis, more rarely Enterococcus spp., Staphylococcus aureus, Listeria monocy-
togenes, group A streptococcus (GAS), and Hib may be seen [3, 5].
• Infants >3 months (90 days) and children: Streptococcus pneumoniae and
N. meningitidis are common pathogens. Group A streptococcus, GBS, Hib, and
other gram-negative microorganisms are less commonly seen.
• In adolescents: Neisseria meningitidis is the most common pathogen [3, 5].
Escherichia coli, Klebsiella spp., and Pseudomonas spp. cause %14 cases of gram-negative ABM in infants worldwide [9].
31 Gram-Negative Bacterial Meningitis inChildren andHearing Loss
https://t.me/medicina_free
According to geographical regions, pneumococci in North America and menin­gococci in Europe and sub-Saharan Africa are the most common causes of ABM [3,
5]. Meningococcal serogroup B and A meningitis are more common in Europe and
Africa, respectively [3, 5]. However, meningococcal serogroup distribution may change over the years, even in the same geographical area. So, the actual epidemiology- based variations of different countries or regions should be checked for pretravel vaccination [3, 5].
Gram-negative bacillary meningitis primarily occurs in specic situations, including neonatal, post-traumatic, healthcare-associated, post-brain surgery, and spontaneous gram-negative meningitis in adults and VPS infections [3, 5]. Most neonates with meningitis are infected with E. coli strains containing K1 capsular polysaccharides, which can help the organism to be saved from host defense [3, 5]. In newborns and infants, gram-negative bacillary meningitis may be associated with neural tube defects and urinary tract anomalies. Any condition that disrupts the dura mater integrity, such as neurosurgery or trauma, may predispose to meningeal infec­tion and cause gram-negative bacterial meningitis. This probability is relatively increased when antimicrobial prophylaxis is given predominantly for gram-positive coverage to prevent surgical site infection [2, 5].
473
31.4 Pathogenesis andPathophysiology
The most common mechanism in the invasion of the causative agent to the central nervous system (CNS) is the nasopharyngeal colonization of the pathogen, such as Hib, meningococcus, and pneumococcus, usually acquired by droplets rst, then passing through the blood circulation and penetrating the subarachnoid space from the capillary endothelium.
The second way is the direct entry of the microorganism to the CNS by contigu­ous infections, such as complicated sinusitis, mastoiditis, septic cerebral venous thrombus, or by direct spread from a congenital neural tube defect or cerebrospinal uid (CSF)-related pilonidal sinus, trauma, neurosurgery, CSF leakage, or through medical devices such as VPSs, and cochlear implants. This pathogenetic mechanism is more likely for gram-negative bacillary meningitis. However, in cases of dural tear and/or CSF leakage secondary to head trauma, pathogens that tend to colonize the mucosa and skin, such as pneumococci and staphylococci, may also be seen.
Thirdly, meningitis may develop with the invasion of the CNS following bacte­remia from a different localized source, such as a catheter infection, infective endo­carditis, or complicated urinary tract infection [5]. This mechanism is more common in patients with immunodeciencies, such as meningococcal meningitis in terminal complement deciencies.
Most signicant meningitis pathogens have surface components such as mbriae or pili that increase mucosal colonization. Meningococci use a variety of receptors, including the platelet-activating factor receptor, beta-2 adrenergic receptors, and CD147, for adhesion through type IV pili. Outer membrane proteins (OpC and OpA) also contribute to establishing and maintaining adhesion [10, 11]. Also,